Microsoft And NVIDIA Partnership Expansion Will Present AI Innovations For Health Services
JAKARTA - Microsoft announced the expansion of its partnership with NVIDIA, in presenting accelerated AI-generational, cloud, and computing technologies for health and biological service organizations.
By unifying the expertise of each company, this collaboration is expected to accelerate clinical research and drug discovery, improve medical image-based diagnostic technology, and improve access to precision treatment.
"Through this collaboration, we aim to help the industry open breakthroughs in health services, make services more appropriate, accessible, and effective to provide meaningful differences in patient life globally," said Peter Durlach, vice president of the company, Health & Life Sciences, Microsoft in its announcement.
NVIDIA's vice president of health services, Kimberly Powell also hopes that the convergence of AI and cloud computing can change patient services, and have a meaningful impact on patients around the world.
This expanded collaboration will expand opportunities for healthcare providers, pharmaceutical and biotechnology companies, as well as developers of medical devices to innovate quickly in clinical research, drug discovery, and service administration with increased efficiency and effectiveness.
SEE ALSO:
Through technology from the hosted NVIDIA DGX Cloud in Microsoft Azure, the two companies introduced NVIDIA BioNeMo, a generative AI platform for drug discovery that could improve the application of models for drug discovery applications.
While the combination of Azure, NVIDIA MONAI (Medical Open Network for AI), and Nuance Precision Imaging Network (PIN) allows development to improve clinical research and provide treatment with AI diagnostic technology.
Once this service is available, Microsoft will also invite researchers, doctors, and developers to explore this advanced model and implement it as a endpoint in the Azure AI Model Catalog.